Is Semaglutide Oral or Injection — or Can It Be Either?

Step 1: understanding what separates the two forms

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness, slows how quickly the stomach empties, and reduces appetite. That mechanism is identical whether the medicine reaches your bloodstream via a weekly pen under the skin or a daily tablet absorbed through the stomach lining.

The difference lies in how the molecule is delivered. The injection goes directly into subcutaneous tissue (the abdomen, thigh or upper arm) and is absorbed reliably at a consistent rate each week. The tablet uses a co-formulation with an absorption enhancer called SNAC, which allows semaglutide to pass through the stomach wall. Because stomach acid and food interfere with that process, the tablet comes with specific rules: it must be taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to about 120 ml), and you need to wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines.

Storage is another practical fork in the road. The injection pen must be kept refrigerated between 2°C and 8°C (consult the Patient Information Leaflet for the exact rules on room-temperature use). The tablet needs no refrigeration at all, which some people find considerably more convenient for travel or unpredictable schedules.

You can read a closer look at how the formats compare day-to-day on our semaglutide oral vs injection page.

Step 2: the dosing ladders, how each form is titrated

Both forms are started at a low dose and stepped up gradually, allowing the body to adjust and reducing the chance of gastrointestinal side effects. The prescriber controls the pace of titration; the schedules below are factual descriptions, not instructions.

The injection begins at 0.25 mg weekly and moves through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, typically at roughly four-week intervals. The MHRA approved a higher 7.2 mg dose in January 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026, currently for adults with a BMI of 30 or above. Starting dose for the 7.2 mg pathway remains 0.25 mg; 7.2 mg is the ceiling.

The tablet climbs a different ladder: 1.5 mg daily, then 4 mg, then 9 mg, arriving at a 25 mg maintenance dose, with at least one month at each level. People who are already stable on the 2.4 mg weekly injection may be able to move directly to the 25 mg tablet, but that is a clinical decision made with a prescriber, not something to self-manage.

One thing worth knowing if you are planning ahead: the tablet's 30-minute morning window is non-negotiable from a clinical standpoint. If your mornings are reliably rushed (school run, early commute, or even the week after payday when habits slip) it is worth raising that honestly at consultation. The injection's once-weekly schedule sidesteps that daily discipline entirely.

For a more detailed look at the tablet schedule specifically, the semaglutide tablets page covers it fully.

Step 3: what trial evidence says about outcomes for each form

Clinical trial results are not a promise of what any individual will experience, but they give the clearest available picture of how well each form works in practice.

The injection at 2.4 mg was studied in the STEP 1 trial (68 weeks, adults without diabetes): participants lost around 15% of body weight on average, compared with roughly 2.4% on placebo. The STEP 1 paper in the New England Journal of Medicine remains the most cited reference point for Wegovy's injection results. At 7.2 mg, more recent data suggest average losses approaching 20.7% over 72 weeks, narrowing the gap with tirzepatide.

The tablet was assessed in the OASIS 4 trial (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, against placebo). Average weight loss was around 13.6% regardless of adherence. Among participants who stayed fully adherent to treatment throughout the trial, the figure rose to approximately 16.6%. That higher number is clinically meaningful, but it only applies to the consistently adherent group, quoting it without that context would misrepresent the trial.

The honest summary is that the injection has more trial data across more dose levels and, at equivalent maintenance doses, shows modestly greater average weight reduction than the tablet. Whether that gap matters for a specific individual depends on a range of factors a prescriber is best placed to weigh. Our page on oral versus injection effectiveness explores this in more detail.

Step 4: which form might suit you, and how that decision gets made

People often come to this question with a strong preference already in mind. Needle anxiety is real, and for many people the prospect of a weekly self-injection is the single biggest barrier. For them the tablet removes that barrier entirely. Others find a once-weekly routine easier to maintain than a daily one, particularly if mornings are variable. If you are still weighing up those practicalities, our guide to choosing between semaglutide tablets or injections walks through the key considerations in more detail.

Eligibility lines differ slightly too. The injection is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. The tablet carries the same thresholds. For both, lower BMI cut-offs apply for certain ethnic backgrounds under UK guidance. BMI alone is not the whole picture, a prescriber considers your full health history, any existing conditions and your current medicines before recommending either form.

If you take other oral medicines in the morning, the tablet's 30-minute wait may require some reorganisation of your routine. The injection avoids that interaction window altogether. Oral contraceptives are a separate consideration for tirzepatide users, but for semaglutide specifically, NHS guidance does not currently flag equivalent evidence of reduced pill effectiveness.

Cost is part of the picture too. You can find an overview of what treatment pricing typically includes on the Wegovy pill price page, and if you are specifically deciding between the Wegovy formats, our comparison of Wegovy oral or injection covers the practical and clinical differences side by side. More broadly, our weight-loss treatment overview covers the full range of options available through nume for anyone still deciding which direction to go.

The NHS medicines page for semaglutide is also a reliable reference for how both forms are described at a patient level, including side effects and precautions.

If you are weighing up the formats and want a clinical opinion on which might suit your situation, speaking to our prescribers is the straightforward next step. There is no obligation and no cost to the consultation itself.